Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BEAM

BEAM - Beam Therapeutics Inc Stock Price, Fair Value and News

$25.17-0.42 (-1.64%)
Market Closed

44/100

BEAM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

44/100

BEAM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BEAM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BEAM Price Action

Last 7 days

-5.2%

Last 30 days

-3.2%

Last 90 days

-8%

Trailing 12 Months

0.4%

BEAM RSI Chart

BEAM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BEAM Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-32.05

Price/Sales (Trailing)

18.35

EV/EBITDA

-58.5

Price/Free Cashflow

-7.12

BEAM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

139.7M

Rev. Growth (Yr)

279.52%

Rev. Growth (Qtr)

1.1K%

BEAM Earnings

Earnings (TTM)

-80.0M

Earnings Growth (Yr)

370.38%

Earnings Growth (Qtr)

316.71%

BEAM Profitability

EBT Margin

-43.71%

Return on Equity

-6.46%

Return on Assets

-5.4%

Free Cashflow Yield

-14.04%

BEAM Investor Care

Shares Dilution (1Y)

21.71%

Diluted EPS (TTM)

-0.82

BEAM Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202563.6M60.3M55.7M139.7M
2024299.2M220.6M142.1M63.5M
202376.7M80.2M81.6M377.7M
202254.1M56.4M58.7M60.9M
202113.0M25.9M38.9M51.8M
202000024.0K
20190000
Get all data in R, Python etc through our Historical Stock Data APIs

About Beam Therapeutics Inc

BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://beamtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES532

Beam Therapeutics Inc Frequently Asked Questions

BEAM is the stock ticker symbol of Beam Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Beam Therapeutics Inc is 2.56 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, BEAM's PE ratio (Price to Earnings) is -32.05 and Price to Sales (PS) ratio is 18.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BEAM PE ratio will change depending on the future growth rate expectations of investors.